Dimethylamino micheliolide fumarate hydrate, its preparation method and use

The reactive crystallization of dimethylamino Micheliolide fumarate hydrate addresses solubility and stability issues, resulting in high-yield, stable, and flowable crystals suitable for high-dose drug formulations without additional adjuvants, enhancing patient compliance.

JP7591224B2Active Publication Date: 2024-11-28ACCENDATECH +1
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2023500114
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-03-26
Publication Date
2024-11-28
Estimated Expiration
2040-03-26

AI Technical Summary

Technical Problem

Existing dimethylamino Micheliolide fumarate compounds face issues with poor water solubility, stability, and poor flowability, leading to challenges in drug formulation and patient compliance due to the need for additional adjuvants and reduced stability.

Method used

A reactive crystallization method is employed to produce dimethylamino Micheliolide fumarate hydrate (crystalline form D) with improved bulk density, fluidity, and stability, using specific solvent mixtures and controlled conditions to achieve large particle size and smooth crystal surfaces.

Benefits of technology

The method results in high-yield, reproducible dimethylamino Micheliolide fumarate hydrate with enhanced stability and flowability, allowing for higher dose capsules without additional adjuvants, improving patient compliance and formulation stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591224000006
    Figure 0007591224000006
  • Figure 0007591224000007
    Figure 0007591224000007
  • Figure 0007591224000008
    Figure 0007591224000008
Patent Text Reader

Abstract

The present invention provides dimethylamino micheliolide fumarate hydrate, its preparation method, and uses. The hydrate is crystalline form D, with high crystallinity, smooth particle surfaces that do not aggregate, high bulk density, good flowability, and good stability and reproducibility. Its preparation method is as follows: dimethylamino micheliolide and fumaric acid are added to a mixed solvent system maintained at a temperature of 30°C to 70°C while stirring to cause reactive crystallization. After the reaction is complete, the system is filtered and the solid obtained is dried under atmospheric pressure to obtain crystalline form D of dimethylamino micheliolide fumarate. This preparation method is simple and has a high product yield, making it suitable for subsequent drug preparation and contributing to mass production.
Need to check novelty before this filing date? Find Prior Art

Description

Detailed Description of the Invention

[0001] [Technical field] The present invention belongs to the technical field of drug crystallization, specifically to dimethylamino micheliolide fumarate hydrate, its preparation method and use.

[0002] [Background technology] Parthenolide is the main active ingredient extracted from feverfew and artemisiifolia, which are medicinal plants of the Asteraceae family, and is a natural sesquiterpene lactone compound. Traditionally, parthenolide has been used mainly to treat diseases such as fever, rheumatoid arthritis, migraine, and toothache. In recent years, research in China and abroad has found that parthenolide also has antitumor effects, but that such compounds are unstable under acidic or alkaline conditions.

[0003] In order to improve its stability, the compound parthenolide is modified to obtain Micheliolide, whose English name is Micheliolide (MCL), which belongs to the guaiane sesquiterpene lactone compound. The relevant literature and patents report that Micheliolide has the effect of treating cancer disease, but its water solubility is relatively poor. In order to improve the water solubility and biological activity, it is reacted under heating in methanol solvent under the condition of triethylamine as a catalyst to obtain a Micheliolide derivative, namely dimethylamino Micheliolide, whose molecular formula is C 17 H 27 NO3, its structural formula is as follows, and its English name is Dimethylaminomicheliolide (DMAMCL). DMAMCL is somewhat improved in terms of water solubility compared with MCL, but it decomposes and is unstable when left for a long time. In order to further improve its water solubility and stability, it is usually prepared in the form of a salt, and the inventor has already found that dimethylaminomicheliolide fumarate is prepared by deriving it from parthenolide. At the same time, patent WO2011 / 131103A1 discloses a micheliolide derivative or its salt, including dimethylaminomicheliolide fumarate, a method for preparing a pharmaceutical composition thereof, and its use in preparing a drug for treating cancer.

[0004] Dimethylaminomikeliolide fumarate has the molecular formula C 21 H 31 It is NO7, has a relative molecular mass of 409, is a white crystalline powder, tasteless and odorless, and dissolves in water, methanol, ethanol, tetrahydrofuran, 1,4-dioxane, acetone, acetonitrile, and isopropyl acetate, and is practically insoluble in cyclohexane, normal hexane, normal heptane, dichloromethane, isopropyl ether, and toluene. Its chemical structure is as follows:

[0005] [ka]

[0006] Polymorphism means that the same substance has different molecular arrangements or three-dimensional structures in its lattice, so that the crystal structures formed are different. According to statistics, 80% of commercially available drugs have polymorphism. Different crystal forms of the same drug have significant differences in physicochemical properties such as color, solubility, melting point, density, hardness, crystal morphology, etc., which further cause quality variations in drug stability, dissolution rate, bioavailability, etc., which affect the post-processing and treatment of products, and to some extent affect the therapeutic effect and safety of drugs. In the process of drug quality control and new drug form design, the study of drug polymorphism has become an essential and important part.

[0007] Chinese patent CN103724307B discloses crystalline form A of dimethylamino micheliolide fumarate and its preparation method, the patent characterizes crystalline form A by using XRPD, and the following 2θ values ​​are shown: 7.10°, 7.58°, 11.72°, 12.26°, 13.30°, 14.24°, 15.70°, 16.38°, 17.04°, 19.02°, 19.86°, 20.14°, 20.66°, 21.20°, 21.78°, 22.64°, 23.58°, 23.8°, 24.48°, 25.02°, 26.02°, 27.02°, 28.02°, 29.02°, 30.02°, 31.02°, 32.02°, 33.02°, 34.02°, 35.02°, 36.02°, 37.02°, 38.02°, 39.02°, 40.02°, 41.02°, 42.02°, 43.02°, 44.02°, 45.02°, 46.02°, 47.02°, 47.02°, 48.02°, 49.02°, 50.02°, 51.02°, 52.02°, 53.02°, 54.02°, 55.02°, 56.02°, 57.02°, 58.02°, 59.02°, 60.02°, 61.02 The crystal form A is prepared by recrystallization in ethyl acetate solvent. The method prepares the product by natural cooling. The crystallization process is controlled by thermodynamics and kinetics at the same time. The crystallization conditions by natural cooling vary greatly under the influence of the environment, and the cooling rate is difficult to control. The product particle size is relatively small, with the main particle size being 35.8 μm. The bulk density is relatively small, reaching only 0.270 g / mL. The angle of repose is 62°. The fluidity is poor, and the quality of the crystal product varies greatly between different batches. At the same time, the stability of crystal form A is relatively poor, it is easy to undergo crystal form transition, and the solid powder also has strong electrostatic effect, which causes dust generation during the production process, which brings many problems to the subsequent processing and treatment.

[0008] Summary of the Invention In order to solve the above problems, the present invention provides dimethylamino micheliolide fumarate hydrate, its preparation method and use, and by using a reactive crystallization method, a crystalline product of dimethylamino micheliolide fumarate hydrate is prepared, which has high crystallinity, high bulk density, good fluidity, large particle size, smooth crystal surface, no aggregation, and high stability, and the preparation method is simple, has a relatively high product yield, has excellent reproducibility, and is conducive to mass production.

[0009] The present invention provides a dimethylamino micheliolide fumarate hydrate, which is in crystalline form D, and the molar ratio of dimethylamino micheliolide fumarate to water is 1:1, and the molecular formula is C17 H 27 NO3·C4H4O4·H2O, which exhibits a weight loss of 3.97%-4.22% before decomposition in thermogravimetry and is characterized by a dehydration endothermic peak at 75±5°C and a characteristic melting peak at 148±5°C in differential scanning calorimetry spectrum, as shown in the thermogravimetry / differential scanning calorimetry spectrum.

[0010] The present invention provides dimethylamino micheliolide fumarate hydrate, the hydrate having X-ray powder diffraction using Cu-Kα radiation and shown at 2θ angles as shown in FIG. 2 as follows: 7.8±0.2°, 11.1±0.2°, 11.4±0.2°, 12.6±0.2°, 12.9±0.2°, 14.4±0.2°, 15.3±0.2°, 17.0±0.2°, 18.7±0.2°, 19.7±0.2°, 20.6±0.2°, 21.0±0.2°, 22.5±0.2°, 23.7±0.2°, 24.3±0.2°, 25.0±0.2°, 26.0±0.2°, 27.0±0.2°, 28.0±0.2°, 29.0±0.2°, 30.0±0.2°, 31.0±0.2°, 32.0±0.2°, 33.0±0.2°, 34.0±0.2°, 35.0±0.2°, 36.0±0.2°, 37.0±0.2°, 38.0±0.2°, 39.0±0.2°, 40.0±0.2°, 41.0±0.2°, 42.0±0.2°, 43.0±0.2°, 44.0±0.2°, 45.0±0.2°, 46.0±0.2°, 47.0±0.2°, 48.0±0.2°, 49.0±0.2°, 50.0±0.2°, 51.0±0.2°, The crystal form D has characteristic peaks at 7.8±0.2°, 25.5±0.2°, and 26.2±0.2°, of which 7.8±0.2° is an initial peak, and the relative intensity of the characteristic peak at 20.6±0.2° is 100%. The crystalline form D is characterized in that it is orthorhombic, has a space group of P212121, and has unit cell parameters of a=8.8346(18)Å, b=14.796(3)Å, c=16.385(3)Å, α=90°, β=90°, γ=90°, and a unit cell volume of 2141.8(8)Å3.

[0011] According to the present invention there is provided a dimethylamino micheliolide fumarate hydrate, said hydrate being further characterized by an X-ray powder diffraction pattern using Cu-Kα radiation and expressed at 2θ angles, having characteristic peaks at 10.5±0.2°, 11.7±0.2°, 12.0±0.2°, 15.6±0.2°, 15.9±0.2°, 16.2±0.2°, 21.3±0.2°, 22.1±0.2°, 23.0±0.2°, 26.4±0.2°, 27.2±0.2°, 28.2±0.2°, 28.6±0.2°, 29.3±0.2°, 30.4±0.2° and 31.1±0.2°.

[0012] The present invention further provides a method for preparing dimethylamino micheliolide fumarate hydrate by reactive crystallization, which is carried out by adding dimethylamino micheliolide and fumaric acid to a mixed solvent system of solvent S1 and solvent S2, the temperature of which is maintained at 30°C-70°C, with stirring, the mass ratio of solvent S2 to solvent S1 is (0-3):1, and the molar ratio of dimethylamino micheliolide to fumaric acid is (1-1.6):1, reacting for 5-10 hours, filtering, and drying at 25-45°C under normal pressure for 6-10 hours to obtain crystalline form D of dimethylamino micheliolide fumarate.

[0013] The solvent S1 is a mixed solvent of water and any one of acetone, tetrahydrofuran, 1,4-dioxane, acetonitrile, and methyl isobutyl ketone.

[0014] The solvent S2 is a mixed solvent of an ester and an ether.

[0015] The ester solvent is selected from one or two of methyl acetate, ethyl acetate, hexyl acetate, and isopropyl acetate.

[0016] The ether solvent is selected from one or two of diethyl ether, methyl ethyl ether, methyl tert-butyl ether, dipropyl ether, dibutyl ether, ethylene glycol dimethyl ether, ethylene glycol monomethyl ether, 1,4-dioxane, tetrahydrofuran, and 2-methyltetrahydrofuran.

[0017] The solvent S1 is a mixed solvent of water and any one of acetone, tetrahydrofuran, 1,4-dioxane, acetonitrile, and methyl isobutyl ketone.

[0018] In the solvent S2, the mass ratio of the ester-based solvent to the ether-based solvent is (1-3:1).

[0019] The mass ratio of the solid raw material of dimethylamino mycheliolide to S1 is 1:(6 to 10).

[0020] The present invention has studied the crystal habit of dimethylamino micheliolide fumarate hydrate, and its scanning electron microscope image is shown in Figure 3. The crystal has regular bulk crystal habit, the particle surface is smooth and not aggregated, the average particle size of the crystal is large, can reach 300 μm, the bulk density is 0.65 g / mL, the repose angle is 32°, the product has high bulk density and good flowability. The crystal form A prepared by natural cooling recrystallization method disclosed in patent CN103724307B has a main particle size of 35.8 um, the bulk density only reaches 0.270 g / mL, the repose angle is 62°, and its scanning electron microscope image is shown in Figure 4. In contrast, the crystal form D product of dimethylamino micheliolide fumarate hydrate provided by the present invention has significantly improved particle size, solving the problem of low bulk density and low flowability of crystal form A product.

[0021] The present invention considers the stability of dimethylamino micheliolide fumarate hydrate, and the anhydrous crystalline compound product is uniformly dispersed in an open Petri dish, the temperature is controlled at 45°C, the humidity is controlled at 75%, the thickness of the sample is less than 5 mm, and the sample is sealed and placed in a desiccator for 30 days. Then, the samples left for 7 days, 14 days, and 30 days are subjected to XRD detection, and compared with the detection results on day 0. The specific spectrum is shown in FIG. 5. The results show that the XRD spectrum does not change obviously. At the same time, the purity analysis is performed on the samples left for 7 days, 14 days, and 30 days, and compared with the purity detection results on day 0, it is found that the purity of the sample on day 7 changes by only 0.015%, the purity of the sample on day 14 changes by only 0.027%, and the purity of the sample on day 30 changes by only 0.046%, indicating that the purity of the sample does not change obviously. The combination of the XRD spectrum and the purity analysis results proves that the stability of dimethylamino micheliolide fumarate hydrate is more excellent.

[0022] The dimethylamino micheliolide fumarate hydrate provided by the present invention can be used to prepare the crystalline form B of the solvent-free compound of dimethylamino micheliolide fumarate, and the preparation method of the crystalline form B is as follows: dimethylamino micheliolide fumarate hydrate is isothermally heated at 80°C to 120°C for 10 min to 30 min to obtain the crystalline form B of the solvent-free compound of dimethylamino micheliolide fumarate, the X-ray powder diffraction spectrum of which is shown in Figure 6, and the 2θ angles are 8.1±0.2°, 10.7±0.2°, 11.5±0.2°, 11.9±0.2°, 13.0±0.2°, 13.3±0.2°, 14.7±0.2°, 15.9±0.2°, 16.1±0.2°, 16.7±0.2°, 17.1±0.2°, 19.0±0.2°, 20.0±0.2°, 21.0±0.2°, 22.0±0.2°, 23.0±0.2°, 24.0±0.2°, 25.0±0.2°, 26.0±0.2°, 27.0±0.2°, 28.0±0.2°, 29.0±0.2°, 30.0±0.2°, 31.0±0.2°, 32.0±0.2°, 33.0±0.2°, 34.0±0.2°, 35.0±0.2°, 36.0±0.2°, 37.0±0.2°, 38.0±0.2°, 39.0±0.2°, 40.0±0.2°, There are characteristic peaks at 19.9±0.2°, 20.3±0.2°, 21.2±0.2°, 21.5±0.2°, 22.1±0.2°, 23.0±0.2°, 23.5±0.2°, 24.4±0.2°, 26.0±0.2°, 26.6±0.2°, 26.9±0.2°, 27.4±0.2°, 27.9±0.2°, 28.6±0.2°, 29.4±0.2°, 30.2±0.2°, and 31.0±0.2°. The scanning electron micrograph is similar to that of FIG. 5, showing that the crystal habit is consistent with a hydrate, that it is bulky, and that the particle size is large.

[0023] The dimethylamino micheliolide fumarate hydrate according to the present invention further provides a pharmaceutical composition which contains a pharma- ceutically acceptable auxiliary and may further contain one, two or more other pharmacologically active ingredients other than dimethylamino micheliolide fumarate hydrate.

[0024] The pharmaceutical adjuvants include, but are not limited to, other non-pharmacologically active ingredients other than the active ingredient, such as dimethylaminomikeliolide fumarate in crystalline form, that can be used in the pharmaceutical compositions described in the present invention, including carriers or auxiliaries, such as fillers, glidants, lubricants, adhesives, stabilizers and / or other auxiliaries.

[0025] The fillers include, but are not limited to, at least one of corn starch, glucose, mannitol, sorbitol, silica, microcrystalline cellulose, sodium carboxymethyl starch, complex starch, pregelatinized starch.

[0026] The glidants include, but are not limited to, at least one of silica, hydrated silica, light anhydrous silicic acid, dry aluminum hydroxide gel, aluminum silicate, magnesium silicate.

[0027] The lubricant includes at least one of, but is not limited to, wheat starch, rice starch, corn starch, stearic acid, calcium stearate, magnesium stearate, hydrated silica, light anhydrous silicic acid, synthetic aluminum silicate, dry aluminum hydroxide gel, talc, magnesium aluminometasilicate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, sucrose fatty acid ester, paraffin, hydrogenated vegetable oil, and polyethylene glycol.

[0028] The pharmaceutical preparation prepared by the pharmaceutical composition according to the present invention is characterized in that said pharmaceutical preparation comprises the pharmaceutical composition in the form of tablets, capsules or granules, more preferably capsules.

[0029] The present invention further provides a use of said dimethylamino micheliolide fumarate hydrate or said pharmaceutical composition in the preparation of a medicament for treating or preventing a disease or condition, preferably a cancer selected from leukemia, breast cancer, prostate cancer, nasopharyngeal cancer, colon cancer, lung cancer, liver cancer, esophageal cancer, gastric cancer, intestinal cancer, renal cancer, oral cancer, Hodgkin's lymphoma, pancreatic cancer, colorectal cancer, cervical cancer, non-Hodgkin's lymphoma, glioma, melanoma, bladder cancer, ovarian cancer, thyroid cancer or Kaposi's sarcoma.

[0030] [Beneficial Effects] The hydrate described in the present invention has good fluidity and is more suitable for the subsequent preparation of drugs. As is well known, the fluidity of the active ingredient itself is usually difficult to meet the filling conditions of capsules or microcapsules, and in order to meet the requirements of the filling conditions for fluidity, it is necessary to add auxiliary agents such as pregelatinized starch, silica and magnesium stearate, so as to achieve the desired dosage form quality and production efficiency. Taking the specification of a capsule of 100 mg as an example, for example, if the active ingredient is another form such as crystalline form A, after adding auxiliary agents, the weight of the capsule contents is about 310 mg, and the maximum 0# capsule shell must be used, and it is not possible to prepare a capsule containing a larger specification, for example, 200 mg of active ingredient. Therefore, patients are forced to increase the capsule dosage or administration frequency to achieve high dosage administration when taking medicine, which significantly reduces the compliance of patients. However, the inventors have found that due to the excellent flowability of dimethylamino micheliolide fumarate hydrate crystalline form D, even without the addition of any auxiliary agent, it is possible to reach an angle of repose of 32°, and therefore, even if the dosage of auxiliary agent is significantly reduced, or even if no auxiliary agent is added, it is possible to achieve the flowability required for the filling conditions of capsules or microcapsules. Also, the reduction in the dosage of auxiliary agent allows the production of capsules with a higher dosage, which significantly improves patient compliance.

[0031] Furthermore, crystalline form D of dimethylamino micheliolide fumarate hydrate allows for a reduction in the amount of auxiliary agents added, or even for no auxiliary agents to be added, whereas crystalline form A has the same fluidity as crystalline form D of the hydrate, and therefore requires the addition of a large amount of auxiliary agents, and is relatively unstable. Therefore, crystalline form D of the hydrate also improves the stability of the formulation.

[0032] In addition, the preparation method of dimethylamino micheliolide fumarate hydrate crystal form D has simple operation steps, relatively high product yield, good reproducibility, high crystallinity, smooth particle surface without aggregation, no static electricity between particles, and high bulk density, which is more conducive to mass production.

[0033] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a thermogravimetric analysis / differential scanning calorimetry spectrum of the dimethylamino micheliolide fumarate hydrate of the present invention.

[0034] FIG. 2 is an X-ray diffraction spectrum of the dimethylamino micheliolide fumarate hydrate of the present invention.

[0035] FIG. 3 is a scanning electron microscope image (40x magnification) of the dimethylamino micheliolide fumarate hydrate of the present invention.

[0036] FIG. 4 is a scanning electron microscope image (magnification: 200 times) of the crystalline form A product prepared by the method disclosed in Patent CN103724307B.

[0037] FIG. 5 is a comparison of the XRD spectra of samples left standing for 0 days, 7 days, 14 days, and 30 days from bottom to top, showing a stability test of the dimethylamino micheliolide fumarate hydrate of the present invention.

[0038] FIG. 6 is an X-ray diffraction spectrum of crystalline form B of the solvent-free compound of dimethylamino micheliolide fumarate of the present invention.

[0039] [Mode for carrying out the invention] The above content of the present invention will be described in more detail below with reference to specific embodiments in the form of examples, but it should not be understood that the scope of the above gist of the present invention is limited to the following examples. All technologies realized based on the above content of the present invention belong to the scope of the present invention.

[0040] Example 1 Preparation of dimethylaminomikeliolide fumarate hydrate While stirring, 0.293 g of dimethylamino mikeliolide and 0.116 g of fumaric acid are added to the mixed solvent system of solvent S1 and solvent S2, the temperature of which is maintained at 30 ° C., the mass of solvent S1 is the same as the mass of solvent S2, of which solvent S1 is composed of 1.598 g of acetone solvent and 0.16 g of water, and solvent S2 is composed of 0.879 g of ethyl acetate and 0.879 g of diethyl ether, and after reacting for 5 h, it is filtered and dried at 25 ° C for 6 h under normal pressure to obtain the crystalline form D product of dimethylamino mikeliolide fumarate. The thermogravimetric analysis / differential scanning calorimetry of the product is consistent with Figure 1, and the thermogravimetric analysis shows that there is a weight loss of 4.22% before decomposition, and the differential scanning calorimetry shows that there is a dehydration endothermic peak at 75 ° C. and a characteristic melting peak at 148 ° C. The X-ray powder diffraction spectrum of the product is consistent with Figure 2, and has characteristic peaks at 7.8°, 11.1°, 11.4°, 12.6°, 12.9°, 14.4°, 15.3°, 17.0°, 18.7°, 19.7°, 20.6°, 21.0°, 22.5°, 23.7°, 24.3°, 25.5°, and 26.2° in terms of diffraction angle 2θ, of which 7.8° is the initial peak and the relative intensity of the characteristic peak at 20.6° is 100%. The X-ray powder diffraction spectrum of the product further has characteristic peaks at 10.5±0.2°, 11.7±0.2°, 12.0±0.2°, 15.6±0.2°, 15.9±0.2°, 16.2±0.2°, 21.3±0.2°, 22.1±0.2°, 23.0±0.2°, 26.4±0.2°, 27.2±0.2°, 28.2±0.2°, 28.6±0.2°, 29.3±0.2°, 30.4±0.2°, and 31.1±0.2° when shown in 2θ angle. The SEM photograph of the crystal morphology is consistent with Figure 4, it is bulk crystal, the average particle size of the particles is large, it can reach 300 μm, its bulk density is 0.646 g / mL, and the angle of repose is 32.5°.

[0041] Example 2 Preparation of dimethylaminomikeliolide fumarate hydrate While stirring, 1.758 g of dimethylamino micheliolide and 0.58 g of fumaric acid are added to the mixed solvent system of solvent S1 and solvent S2, the temperature of which is maintained at 50°C, and the mass of solvent S2 is twice the mass of solvent S1, of which solvent S1 is composed of 12.306 g of tetrahydrofuran solvent and 1.758 g of water, and solvent S2 is composed of 21.096 g of isopropyl acetate and 7.032 g of methyl tert-butyl ether. After reacting for 8 h, the mixture is filtered and dried at 30°C for 10 h under normal pressure to obtain the crystalline form D product of dimethylamino micheliolide fumarate. The thermogravimetric analysis / differential scanning calorimetry of the product is consistent with Figure 1, and the thermogravimetric analysis shows that there is a weight loss of 4.20% before decomposition, and the differential scanning calorimetry shows that there is a dehydration endothermic peak at 78°C and a characteristic melting peak at 150°C. The X-ray powder diffraction spectrum of the product is consistent with Figure 2, and has characteristic peaks at 8.0°, 11.2°, 11.5°, 12.7°, 12.9°, 14.5°, 15.4°, 17.1°, 18.8°, 19.8°, 20.6°, 21.1°, 22.5°, 23.7°, 24.5°, 25.6°, and 26.3° in terms of diffraction angle 2θ, of which 7.8° is the initial peak and the relative intensity of the characteristic peak at 20.6° is 100%. The X-ray powder diffraction spectrum of the product, when shown in 2θ angles, further has characteristic peaks at 10.6°, 11.8°, 12.2°, 15.1°, 15.7°, 16.0°, 21.4°, 22.0°, 22.3°, 23.1°, 27.3°, 28.2°, 28.7°, 29.4°, 30.5°, 30.6°, and 31.3°. The SEM photograph of the crystal morphology is consistent with Figure 4, and it is bulk crystal, the average particle size of the particles is large, which can reach 300 μm, and its bulk density is measured to be 0.655 g / mL and the angle of repose is 32°.

[0042] Example 3 Preparation of dimethylaminomikeliolide fumarate hydrate While stirring, 4.688 g of dimethylamino mikeliolide and 1.16 g of fumaric acid are added to the mixed solvent system of solvent S1 and solvent S2, the temperature of which is maintained at 70 ° C., and the mass of solvent S2 is three times the mass of solvent S1, of which solvent S1 is composed of 39 g of 1,4-dioxane solvent and 7.88 g of water, and solvent S2 is composed of 93.76 g of methyl acetate and 46.88 g of methyl ethyl ether. After reacting for 10 h, the mixture is filtered and dried at 45 ° C for 8 h under normal pressure to obtain the crystalline form D product of dimethylamino mikeliolide fumarate. The thermogravimetric analysis / differential scanning calorimetry of the product is consistent with Figure 1, and the thermogravimetric analysis shows that there is a weight loss of 3.97% before decomposition, and the differential scanning calorimetry shows that there is a dehydration endothermic peak at 75 ° C. and a characteristic melting peak at 145 ° C. The X-ray powder diffraction spectrum of the product is consistent with Figure 2, and has characteristic peaks at 7.8°, 11.0°, 11.4°, 12.5°, 12.8°, 14.4°, 15.3°, 17.0°, 18.7°, 19.7°, 20.6°, 21.0°, 22.4°, 23.7°, 24.3°, 25.4°, and 26.2° in terms of diffraction angle 2θ, of which 7.8° is the initial peak and the relative intensity of the characteristic peak at 20.6° is 100%. The X-ray powder diffraction spectrum of the product, when shown in 2θ angles, further has characteristic peaks at 10.5°, 11.7°, 12.0°, 15.6°, 15.9°, 16.2°, 21.3°, 22.2°, 22.9°, 26.4°, 27.3°, 28.2°, 28.6°, 29.3°, 30.4°, and 31.1°. The SEM photograph of the crystal morphology is consistent with Figure 4, and it is bulk crystal, the average particle size of the particles is large, which can reach 300 μm, and its bulk density is measured to be 0.65 g / mL and the angle of repose is 32°.

[0043] Example 4 Preparation of dimethylaminomikeliolide fumarate hydrate While stirring, 4.102 g of dimethylamino mikeliolide and 1.16 g of fumaric acid are added to the mixed solvent system of solvent S1 and solvent S2, the temperature of which is maintained at 60 ° C., and the mass of solvent S2 is three times the mass of solvent S1, of which solvent S1 is composed of 35.8925 g of acetonitrile solvent and 5.1275 g of water, and solvent S2 is composed of 87.9 g of hexyl acetate and 35.16 g of ethylene glycol dimethyl ether. After reacting for 10 h, the mixture is filtered and dried at 45 ° C for 9 h under normal pressure to obtain the crystalline form D product of dimethylamino mikeliolide fumarate. The thermogravimetric analysis / differential scanning calorimetry of the product is consistent with Figure 1, and the thermogravimetric analysis shows that there is a weight loss of 4.10% before decomposition, and the differential scanning calorimetry shows that there is a dehydration endothermic peak at 80 ° C. and a characteristic melting peak at 150 ° C. The X-ray powder diffraction spectrum of the product is consistent with Figure 2, and has characteristic peaks at 7.8°, 11.1°, 11.4°, 12.6°, 12.9°, 14.4°, 15.4°, 17.0°, 18.8°, 19.8°, 20.6°, 21.0°, 22.5°, 23.7°, 24.4°, 25.5°, and 26.2° in terms of diffraction angle 2θ, of which 7.8° is the initial peak and the relative intensity of the characteristic peak at 20.6° is 100%. The X-ray powder diffraction spectrum of the product, when shown in 2θ angles, further has characteristic peaks at 10.6°, 11.8°, 12.1°, 15.9°, 16.3°, 21.4°, 22.2°, 23.0°, 26.5°, 27.3°, 28.7°, 29.3°, 30.4°, and 31.1°. The SEM photograph of the crystal morphology is consistent with Figure 4, and it is bulk crystal, the average particle size of the particles is large, which can reach 300 μm, and its bulk density is measured to be 0.659 g / mL and the angle of repose is 32.2°.

[0044] Example 5 Preparation of dimethylaminomikeliolide fumarate hydrate While stirring, 0.293 g of dimethylamino mikeliolide and 0.116 g of fumaric acid are added to the mixed solvent system of solvent S1 and solvent S2, the temperature of which is maintained at 30 ° C., the mass of solvent S1 is the same as the mass of solvent S2, of which solvent S1 is composed of 1.598 g of acetonitrile solvent and 0.16 g of water, and solvent S2 is composed of 0.879 g of isopropyl acetate and 0.879 g of ethylene glycol monomethyl ether, and after reacting for 5 h, it is filtered and dried at 25 ° C for 6 h under normal pressure to obtain the crystalline form D product of dimethylamino mikeliolide fumarate. The thermogravimetric analysis / differential scanning calorimetry of the product is consistent with Figure 1, and the thermogravimetric analysis shows that there is a weight loss of 4.22% before decomposition, and the differential scanning calorimetry shows that there is a dehydration endothermic peak at 75 ° C. and a characteristic melting peak at 148 ° C. The X-ray powder diffraction spectrum of the product is consistent with Figure 2, and has characteristic peaks at 7.8°, 11.1°, 11.4°, 12.6°, 12.9°, 14.4°, 15.3°, 17.0°, 18.7°, 19.7°, 20.6°, 21.0°, 22.5°, 23.7°, 24.3°, 25.5°, and 26.2° in terms of diffraction angle 2θ, of which 7.8° is the initial peak and the relative intensity of the characteristic peak at 20.6° is 100%. The X-ray powder diffraction spectrum of the product further has characteristic peaks at 10.5±0.2°, 11.7±0.2°, 12.0±0.2°, 15.6±0.2°, 15.9±0.2°, 16.2±0.2°, 21.3±0.2°, 22.1±0.2°, 23.0±0.2°, 26.4±0.2°, 27.2±0.2°, 28.2±0.2°, 28.6±0.2°, 29.3±0.2°, 30.4±0.2°, and 31.1±0.2° when shown in 2θ angle. The SEM photograph of the crystal morphology is consistent with Figure 4, it is bulk crystal, the average particle size of the particles is large, it can reach 300 μm, its bulk density is measured to be 0.645 g / mL, and the angle of repose is 32°.

[0045] Example 6 Preparation of dimethylaminomikeliolide fumarate hydrate While stirring, 4.688 g of dimethylamino mikeliolide and 1.16 g of fumaric acid are added to the mixed solvent system of solvent S1 and solvent S2, the temperature of which is maintained at 70 ° C., and the mass of solvent S2 is three times the mass of solvent S1, of which solvent S1 is composed of 39 g of methyl isobutyl ketone solvent and 7.88 g of water, and solvent S2 is composed of 46.88 g of methyl acetate, 46.88 g of isopropyl acetate, 23.44 g of tetrahydrofuran and 23.44 g of dibutyl ether. After reacting for 10 h, the mixture is filtered and dried at 45 ° C for 8 h under normal pressure to obtain the crystalline form D product of dimethylamino mikeliolide fumarate. The thermogravimetric analysis / differential scanning calorimetry of the product is consistent with Figure 1, and the thermogravimetric analysis shows that there is a weight loss of 3.97% before decomposition, and the differential scanning calorimetry shows that there is a dehydration endothermic peak at 75 ° C. and a characteristic melting peak at 145 ° C. The X-ray powder diffraction spectrum of the product is consistent with Figure 2, and has characteristic peaks at 7.8°, 11.0°, 11.4°, 12.5°, 12.8°, 14.4°, 15.3°, 17.0°, 18.7°, 19.7°, 20.6°, 21.0°, 22.4°, 23.7°, 24.3°, 25.4°, and 26.2° in terms of diffraction angle 2θ, of which 7.8° is the initial peak and the relative intensity of the characteristic peak at 20.6° is 100%. The X-ray powder diffraction spectrum of the product, when shown in 2θ angles, further has characteristic peaks at 10.5°, 11.7°, 12.0°, 15.6°, 15.9°, 16.2°, 21.3°, 22.2°, 22.9°, 26.4°, 27.3°, 28.2°, 28.6°, 29.3°, 30.4°, and 31.1°. The SEM photograph of the crystal morphology is consistent with Figure 4, and it is bulk crystal, the average particle size of the particles is large, which can reach 300 μm, and its bulk density is measured to be 0.65 g / mL and the angle of repose is 32.3°.

[0046] Example 7 Preparation of dimethylaminomikeliolide fumarate hydrate While stirring, 1.758 g of dimethylamino mikeliolide and 0.58 g of fumaric acid are added to the mixed solvent system of solvent S1 and solvent S2, the temperature of which is maintained at 50 ° C., and the mass of solvent S2 is twice the mass of solvent S1, of which solvent S1 is composed of 12.306 g of methyl isobutyl ketone solvent and 1.758 g of water, and solvent S2 is composed of 21.096 g of methyl acetate and 7.032 g of 2-methyltetrahydrofuran. After reacting for 9 h, the mixture is filtered and dried at 30 ° C for 10 h under normal pressure to obtain the crystalline form D product of dimethylamino mikeliolide fumarate. The thermogravimetric analysis / differential scanning calorimetry of the product is consistent with Figure 1, and the thermogravimetric analysis shows that there is a weight loss of 4.20% before decomposition, and the differential scanning calorimetry shows that there is a dehydration endothermic peak at 78 ° C. and a characteristic melting peak at 150 ° C. The X-ray powder diffraction spectrum of the product is consistent with Figure 2, and has characteristic peaks at 8.0°, 11.2°, 11.5°, 12.7°, 12.9°, 14.5°, 15.4°, 17.1°, 18.8°, 19.8°, 20.6°, 21.1°, 22.5°, 23.7°, 24.5°, 25.6°, and 26.3° in terms of diffraction angle 2θ, of which 7.8° is the initial peak and the relative intensity of the characteristic peak at 20.6° is 100%. The X-ray powder diffraction spectrum of the product, when shown in 2θ angles, further has characteristic peaks at 10.6°, 11.8°, 12.2°, 15.1°, 15.7°, 16.0°, 21.4°, 22.0°, 22.3°, 23.1°, 27.3°, 28.2°, 28.7°, 29.4°, 30.5°, 30.6°, and 31.3°. The SEM photograph of the crystal morphology is consistent with Figure 4, and it is bulk crystal, the average particle size of the particles is large, which can reach 300 μm, and its bulk density is measured to be 0.65 g / mL and the angle of repose is 32°.

[0047] Example 8 Preparation of dimethylaminomikeliolide fumarate hydrate While stirring, 4.102 g of dimethylamino micheliolide and 1.16 g of fumaric acid are added to the mixed solvent system of solvent S1 and solvent S2, the temperature of which is maintained at 60°C, and the mass of solvent S2 is three times the mass of solvent S1, of which solvent S1 is composed of 35.8925 g of tetrahydrofuran solvent and 5.1275 g of water, and solvent S2 is composed of 87.9 g of methyl acetate and 35.16 g of 1,4-dioxane. After reacting for 10 h, the mixture is filtered and dried at 45°C for 9 h under normal pressure to obtain the crystalline form D product of dimethylamino micheliolide fumarate. The thermogravimetric analysis / differential scanning calorimetry of the product is consistent with Figure 1, and the thermogravimetric analysis shows that there is a weight loss of 4.10% before decomposition, and the differential scanning calorimetry shows that there is a dehydration endothermic peak at 80°C and a characteristic melting peak at 150°C. The X-ray powder diffraction spectrum of the product is consistent with Figure 2, and has characteristic peaks at 7.8°, 11.1°, 11.4°, 12.6°, 12.9°, 14.4°, 15.3°, 17.0°, 18.7°, 19.7°, 20.6°, 21.0°, 22.5°, 23.7°, 24.3°, 25.5°, and 26.2° in terms of diffraction angle 2θ, of which 7.8° is the initial peak and the relative intensity of the characteristic peak at 20.6° is 100%. The X-ray powder diffraction spectrum of the product further has characteristic peaks at 10.5±0.2°, 11.7±0.2°, 12.0±0.2°, 15.6±0.2°, 15.9±0.2°, 16.2±0.2°, 21.3±0.2°, 22.1±0.2°, 23.0±0.2°, 26.4±0.2°, 27.2±0.2°, 28.2±0.2°, 28.6±0.2°, 29.3±0.2°, 30.4±0.2°, and 31.1±0.2° when shown in 2θ angle. The SEM photograph of the crystal morphology is consistent with Figure 4, it is bulk crystal, the average particle size of the particles is large, it can reach 300 μm, its bulk density is measured to be 0.654 g / mL, and the angle of repose is 32.1°.

[0048] Example 9 Preparation of dimethylaminomikeliolide fumarate hydrate While stirring, 0.293 g of dimethylamino mikeliolide and 0.116 g of fumaric acid are added to the mixed solvent system of solvent S1 and solvent S2, the temperature of which is maintained at 30°C, and the mass of solvent S1 is the same as that of solvent S2, of which solvent S1 is composed of 1.598 g of acetone solvent and 0.16 g of water, and solvent S2 is composed of 0.879 g of isopropyl acetate and 0.879 g of dipropyl ether. After reacting for 7 h, the product is filtered and dried at 25°C for 6 h under normal pressure to obtain the crystalline form D product of dimethylamino mikeliolide fumarate. The thermogravimetric analysis / differential scanning calorimetry of the product is consistent with Figure 1, and the thermogravimetric analysis shows that there is a weight loss of 4.22% before decomposition, and the differential scanning calorimetry shows that there is a dehydration endothermic peak at 75°C and a characteristic melting peak at 148°C. The X-ray powder diffraction spectrum of the product is consistent with Figure 2, and has characteristic peaks at 7.8°, 11.0°, 11.4°, 12.5°, 12.8°, 14.4°, 15.3°, 17.0°, 18.7°, 19.7°, 20.6°, 21.0°, 22.4°, 23.7°, 24.3°, 25.4°, and 26.2° in terms of diffraction angle 2θ, of which 7.8° is the initial peak and the relative intensity of the characteristic peak at 20.6° is 100%. The X-ray powder diffraction spectrum of the product, when shown in 2θ angles, further has characteristic peaks at 10.5°, 11.7°, 12.0°, 15.6°, 15.9°, 16.2°, 21.3°, 22.2°, 22.9°, 26.4°, 27.3°, 28.2°, 28.6°, 29.3°, 30.4°, and 31.1°. The SEM photograph of the crystal morphology is consistent with Figure 4, and it is bulk crystal, the average particle size of the particles is large, which can reach 300 μm, and its bulk density is measured to be 0.645 g / mL and the angle of repose is 32.3°.

[0049] Example 10 Preparation of crystalline form B of the solvent-free compound dimethylaminomikeliolide fumarate. 0.1 g of the product of Example 1 was weighed into a variable temperature X-ray diffractometer and heated at 80°C for 30 min. The XRD spectrum of the sample analysis was consistent with Figure 6, which demonstrated that crystalline form B of the solvent-free compound of dimethylaminomikeliolide fumarate was obtained. The solid scanning electron micrograph was consistent with the morphology of Figure 5, and the bulk crystal habit was maintained.

[0050] Example 11 Preparation of crystalline form B of the solvent-free compound dimethylaminomikeliolide fumarate. 0.15 g of the product of Example 3 was weighed into a variable temperature X-ray diffractometer and heated at 120°C for 10 min. The XRD spectrum of the sample analysis was consistent with that shown in Figure 6, which demonstrated that crystalline form B of the solvent-free compound of dimethylaminomikeliolide fumarate was obtained. The solid scanning electron micrograph showed the morphology consistent with that shown in Figure 5, and the bulk crystal habit was maintained.

[0051] Example 12 Preparation of crystalline form B of the solvent-free compound dimethylaminomikeliolide fumarate. 0.1 g of the product of Example 4 was weighed into a variable temperature X-ray diffractometer and heated at 100°C for 20 min. The XRD spectrum of the sample analysis was consistent with that shown in Figure 6, which demonstrated that crystalline form B of the solvent-free compound of dimethylaminomikeliolide fumarate was obtained. The solid scanning electron micrograph showed the morphology consistent with that shown in Figure 5, and the bulk crystal habit was maintained.

[0052] Example 13 The recipe for preparing capsule 1 of crystalline form A is as follows:

[0053] [Table 1]

[0054] The process is as follows: (1) sieve the crystal form A through 100 mesh sieve, find it difficult to sieve, there is a lot of residue, and static electricity is large after sieving; (2) sieve pregelatinized starch and silica through 80 mesh sieve, then mix with the crystal form A in a ziplock bag for 5 minutes; (3) sieve magnesium stearate through 80 mesh sieve, then mix with the above mixed powder in a ziplock bag for 1 minute; (4) fill into 0# gelatin capsules manually.

[0055] As is evident from the detection results, the capsule of this example has an angle of repose of 32.91°, which is close to the flowability data of the hydrate crystal form D measured in Example 1.

[0056] Example 14 Preparation of capsule formulation 2 of crystalline form A The formula of Example 13 is repeatedly adopted, and the following process is used: (1) Form A is sieved with pregelatinized starch through 80 mesh sieve, the sieving effect is improved, but it is not ideal and the static electricity is relatively large; (2) Silica is sieved through 80 mesh sieve and then mixed with the above mixed powder in a ziplock bag for 3 minutes; (3) Magnesium stearate is sieved through 80 mesh sieve and then mixed with the above mixed powder in a ziplock bag for 1 minute; (4) Fill into 0# gelatin capsule manually.

[0057] From the detection results, it is clear that the capsule of this embodiment has an angle of repose of 32.88°, which is close to the fluidity of the hydrate crystal form D of Example 5. Further influencing factor experiments are to be carried out.

[0058] Example 15 The recipe for preparing capsules of hydrate crystal form D is as follows, without any other auxiliary agents:

[0059] [Table 2]

[0060] The process is as follows: (1) The amount of hydrated crystal form D prepared in Example 1 is sieved through a 80 mesh sieve; (2) Fill a 3# gelatin capsule, lightly spread the raw material evenly, cover the capsule cap, and perform the influencing factor experiment.

[0061] Example 16 Influence factor experiment A. High temperature test 100 capsules of the capsule products of Examples 14 and 15 are placed in an open Petri dish, and then placed in an incubator at 60°C. Samples are taken on the 5th and 10th days, respectively. Observe the properties, test for related substances, and measure the content.

[0062] B. High humidity test 100 capsules of Examples 14 and 15 are placed in an open Petri dish, and then placed in a sealed container with a relative humidity of 90±5% (saturated potassium nitrate solution), and sampled on the 5th and 10th days, respectively. Observe the properties, test for related substances, and measure the content.

[0063] C. Strong light irradiation test 100 capsules of the capsule products of Examples 14 and 15 are placed in an open Petri dish, irradiated under fluorescent light of 4500±500LX, and sampled on the 5th and 10th days, respectively. Observe the properties, test for related substances, and measure the content.

[0064] The experimental results are summarized below.

[0065] [Table 3]

[0066] [Table 4]

[0067] As can be seen from the above results, in the influencing factor experiments of capsules of crystalline form D of the hydrate with similar fluidity, the MCL (micelliolide) content within 5 days is not significantly changed, but in the experiments of capsules of crystalline form A, the MCL content is significantly increased after 5 days. Therefore, due to the excellent fluidity of crystalline form D of the hydrate, the capsules can be prepared without adding auxiliary agents and applied to clinical practice. On the contrary, even if the fluidity of capsules of crystalline form A is improved by increasing the amount of auxiliary agents and optimizing the process, its stability is significantly inferior to that of crystalline form D of the hydrate. Therefore, crystalline form D of the hydrate is superior to capsules of crystalline form A in terms of preparation process, stability and compliance. [Brief description of the drawings]

[0068] [Figure 1] 1 is a thermogravimetric / differential scanning calorimetry spectrum of dimethylamino micheliolide fumarate hydrate of the present invention. [Diagram 2] 1 is an X-ray diffraction spectrum of dimethylamino micheliolide fumarate hydrate of the present invention. [Diagram 3] FIG. 2 is a scanning electron microscope image (40x magnification) of dimethylamino micheliolide fumarate hydrate of the present invention. [Figure 4] FIG. 2 is a scanning electron microscope image (magnification 200 times) of the crystalline form A product prepared by the method disclosed in patent CN103724307B. [Diagram 5] 1 is a comparison of the XRD spectra of samples left standing for 0 days, 7 days, 14 days, and 30 days, from bottom to top, in a stability test of the dimethylamino micheliolide fumarate hydrate of the present invention. [Figure 6] 1 is an X-ray diffraction spectrum of the crystalline form B of the solvent-free compound of dimethylamino micheliolide fumarate of the present invention.

Claims

1. Dimethylaminomikeliolide fumarate hydrate, the hydrate being in crystalline form D, the molar ratio of dimethylaminomikeliolide fumarate to water being 1:1, and the molecular formula being C 17 H 27 NO 3 ・C 4 H 4 O 4 ・H 2 O, which has a weight loss of 3.97% to 4.22% before decomposition in thermogravimetric analysis, and a dehydration endothermic peak at 75±5°C and a characteristic melting peak at 148±5°C in differential scanning calorimetry spectrum. The hydrate has X-ray powder diffraction using Cu-Kα radiation and 2θ angles of 7.8±0.2°, 11.1±0.2°, 11.4±0.2°, 12.6±0.2°, 12.9±0.2°, 14.4±0.2°, 15.3±0.2°, 17.0±0.2°, 18.7±0.2°, 19.7±0.2°, 20.6±0.2°, and 21. The crystal form D has characteristic peaks at 22.0±0.2°, 22.5±0.2°, 23.7±0.2°, 24.3±0.2°, 25.5±0.2°, and 26.2±0.2°, of which 7.8±0.2° is an initial peak, and the relative intensity of the characteristic peak at 20.6±0.2° is 100%. The crystal form D is an orthorhombic crystal system with a space group of P2. 1 2 1 2 1 with unit cell parameters a=8.8346(18) Å, b=14.796(3) Å, c=16.385(3) Å, α=90°, β=90°, γ=90° and a unit cell volume of 2141.8(8) Å3.

2. 2. The dimethylamino micheliolide fumarate hydrate of claim 1, wherein the hydrate further exhibits characteristic peaks in the X-ray powder diffraction using Cu-Kα radiation and expressed at 2θ angles at 10.5±0.2°, 11.7±0.2°, 12.0±0.2°, 15.6±0.2°, 15.9±0.2°, 16.2±0.2°, 21.3±0.2°, 22.1±0.2°, 23.0±0.2°, 26.4±0.2°, 27.2±0.2°, 28.2±0.2°, 28.6±0.2°, 29.3±0.2°, 30.4±0.2°, and 31.1±0.2°.

3. Prepare by reactive crystallization: Add dimethylamino micheliolide and fumaric acid to the mixed solvent system of solvent S1 and solvent S2, which is maintained at a temperature of 30°C to 70°C, while stirring, the mass ratio of solvent S2 to solvent S1 is (1-3):1, and the molar ratio of dimethylamino micheliolide to fumaric acid is (1-1.6):1, react for 5-10 hours, filter, and dry at 25-45°C under normal pressure for 6-10 hours to obtain crystalline form D of dimethylamino micheliolide fumarate; The solvent S1 is a mixed solvent of any one of acetone, tetrahydrofuran, 1,4-dioxane, acetonitrile, and methyl isobutyl ketone and water; The solvent S2 is a mixed solvent of an ester and an ether, The ester solvent may be selected from one or two of methyl acetate, ethyl acetate, hexyl acetate, and isopropyl acetate; The ether solvent may be selected from one or two of diethyl ether, methyl ethyl ether, methyl tert-butyl ether, dipropyl ether, dibutyl ether, ethylene glycol dimethyl ether, ethylene glycol monomethyl ether, 1,4-dioxane, tetrahydrofuran, and 2-methyltetrahydrofuran; A method for preparing dimethylaminomikeliolide fumarate hydrate according to any one of claims 1 to 2.

4. In the solvent S1, the mass ratio of any one of acetone, tetrahydrofuran, 1,4-dioxane, acetonitrile, and methyl isobutyl ketone to water is (5 to 10):1; In the solvent S2, the mass ratio of the ester-based solvent to the ether-based solvent is (1 to 3):1; The mass ratio of the solid raw material of dimethylamino myceliolide to S1 is 1: (6-10); The method for preparing dimethylamino micheliolide fumarate hydrate according to claim 3.

5. The method for preparing crystalline form B of the solvent-free compound of dimethylaminomikeliolide fumarate includes isothermally heating dimethylaminomikeliolide fumarate hydrate at 80°C to 120°C for 10 min to 30 min to obtain crystalline form B of the solvent-free compound of dimethylaminomikeliolide fumarate. The use of dimethylaminomikeliolide fumarate hydrate according to claim 1 for preparing crystalline form B of the solvent-free compound of dimethylaminomikeliolide fumarate.

6. The pharmaceutical composition of dimethylamino micheliolide fumarate hydrate according to claim 1, comprising pharma- ceutically acceptable auxiliaries and may further comprise one, two or more pharmacologically active ingredients other than dimethylamino micheliolide fumarate hydrate.

7. The pharma- ceutical acceptable auxiliary agent includes other non-pharmacologically active ingredients other than the active ingredient, such as dimethylaminomycheliolide fumarate in crystalline form; The pharmaceutical composition of claim 6.

8. The other non-pharmacologically active ingredients may be fillers, glidants, lubricants, adhesives, stabilizers and / or other auxiliary carriers or excipients. The pharmaceutical composition of claim 7.

9. The filler comprises at least one of corn starch, glucose, mannitol, sorbitol, silica, microcrystalline cellulose, sodium carboxymethyl starch, complex starch, and pregelatinized starch; The glidant comprises at least one of silica, hydrated silica, light anhydrous silicic acid, dry aluminum hydroxide gel, aluminum silicate, and magnesium silicate; The pharmaceutical composition of claim 8, wherein the lubricant comprises at least one of wheat starch, rice starch, corn starch, stearic acid, calcium stearate, magnesium stearate, hydrated silica, light anhydrous silicic acid, synthetic aluminum silicate, dried aluminum hydroxide gel, talc, magnesium aluminometasilicate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, sucrose fatty acid ester, paraffinic, hydrogenated vegetable oil, and polyethylene glycol.

10. A pharmaceutical formulation prepared by the pharmaceutical composition according to claim 6, characterized in that the pharmaceutical composition is in the form of tablets, capsules or granules.

11. Use of dimethylamino micheliolide fumarate hydrate as described in claim 1 or the pharmaceutical composition as described in claim 6 in the preparation of a medicament for treating or preventing a disease or condition, wherein the disease or condition is a cancer selected from leukemia, breast cancer, prostate cancer, nasopharyngeal cancer, colon cancer, lung cancer, liver cancer, esophageal cancer, gastric cancer, intestinal cancer, renal cancer, oral cancer, Hodgkin's lymphoma, pancreatic cancer, colorectal cancer, cervical cancer, non-Hodgkin's lymphoma, glioma, melanoma, bladder cancer, ovarian cancer, thyroid cancer or Kaposi's sarcoma.

Citation Information

Patent Citations

  • Dimethylaminomicheliolide fumarate crystal form C and preparation method thereof

    CN111303097A

  • Micheliolide dimethylamine fumarate crystal form E and preparation method thereof

    CN111303098A

  • Micheliolide dimethylamine fumarate crystal form F and preparation method thereof

    CN111303099A

  • Hydrate of micheliolide dimethylamine fumarate, preparation method and application thereof

    CN111303100A

  • Sphaelactone derivatives, their pharmaceutical compositions, preparation methods and uses

    WO2011131103A1